Derya ÇAYIR, Mehmet BOZKURT, Salih Sinan GÜLTEKİN, Aynur TURAN

Androjen-Deprivasyon tedavisi ile regrese olan kemik metastazının sintigrafik değerlendirmesi

99mTc-metilen difosfonat (MDP) tüm vücut kemik sintigrafisi prostat kanserinin kemik metastazlarını değerlendirmede sıklıkla kullanılmaktadır. Anatomik görüntüleme yöntemleri ile saptanamayan malign lezyonların fonksiyonel olarak izlenebilmesi ve tedaviye yanıtının değerlendirilebilmesi açısından nükleer tıp tetkikleri çok değerlidir. Bununla birlikte sintigrafik yöntemlerin rezolüsyon ve anatomik detayları belirlemede bazı radyolojik tetkiklere göre sınırlı olabildiği bilinmektedir. Kemik metastazlarının tedavisinde sıklıkla kombine sistemik tedaviler tercih edilmekte olup, androjen-deprivasyon tedavisi (ADT) tek başına nadiren etkilidir. Burada bilgisayarlı tomografi ile saptanamayan, 18 ay ADT ile regrese olan kemik metastazlı nadir prostat kanserli bir olguyu sunuyoruz.

Anahtar Kelimeler:

Tüm vücut görüntüleme, Prostat kanseri, Metastaz, Tomografi

Complete scintigraphic resolution of a bone metastasis after androgen-deprivation therapy

99mTc-methylene diphosphonate (MDP) whole body bone scintigraphy is a frequently used imaging method for the evaluation of the bone metastases of prostate cancer. Nuclear medicine imaging modalities are very valuable in terms of functional assessment and treatment response assessment of the malign lesions that cannot be detected by anatomic imaging methods. However, it is known that some scintigraphic studies may have a relatively limited role in defining resolution and anatomical details of the lesion, compared to some radiological imaging modalities. Androgen-deprivation therapy (ADT) alone is rarely effective for the treatment of bone metastases, on that account combined systemic therapies are often preferred. Here we present a rare case of prostate cancer with radiologically undetectable bone metastasis evident on scintigraphy that has disappeared after 18 months of ADT.

Keywords:

Whole body scan, Prostate cancer, Metastasis, Tomography,

PDF

___

1. Van den Wyngaert T, Strobel K, Kampen WU, Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016;43:1723-38.
2. Bozkurt MF, Dede Z, Burak Z, Ak I, Bekis R, Degirmenci B, et al. Procedure Guideline For Bone Scintigraphy. Turk J Nucl Med. 2001;10:97-102.
3. Kölükçü E, Beyhan M, Atılgan D. Factors affecting complications of transrectal ultrasound-guided prostate biopsy: A cohort study with 403 patients in a single center. J Surg Med. 2019;3(2):183-6.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
5. O'Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int. 2003;92:685-9.
6. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7.
7. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017;71:630-42.
8. Mcleod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International. 2006;97:247-54.